stockrow
Friday 6 November 2026
Export NEPH’s income statement to Excel — free account
Nephros Inc.
NEPH Healthcare Medical Instruments & Supplies
Nephros Inc.’s revenue for fiscal 2025 (year ended December 2025) was $18.8 million, up 32.7% from fiscal 2024.
- Revenue
- +18.0%
- EPS
- +66.7%
- Free cash flow
- −251.5%
Quarter to September 2026, against a year earlier
2.82
0.27
−8.74%
Follow NEPH
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 5 Nov | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
46.12 | 45.29 | 22.91 | 21.10 |
P/S ratio |
2.76 | 1.66 | 1.87 | 1.87 | |
P/FCF ratio |
34.07 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
225.16 | (18.99) | 56.92 | (268.68) | |
P/B ratio |
5.08 | 2.97 | 3.24 | 3.21 | |
Price to Tangible BV |
5.78 | 3.35 | 3.60 | 3.55 | |
EV/Sales |
2.47 | 1.45 | 1.64 | 1.66 | |
EV/EBITDA |
36.10 | 34.53 | 19.32 | 18.39 | |
EV/Operating CF |
28.20 | (79.68) | (51.54) | (39.30) | |
EV/FCF |
30.52 | (58.62) | (43.34) | (34.55) | |
Quick Ratio |
2.82 | 2.98 | 2.63 | 3.37 | |
Current Ratio |
4.06 | 4.55 | 4.07 | 5.50 | |
Net Debt/EBITDA |
(108.00) | (32.40) | (3.78) | (8.58) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
1.51 | 1.50 | 1.48 | 1.51 | |
Operating CF/Net income |
3.71 | (11.94) | 0.57 | (0.29) | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
— | — | 1,213.00 | — | |
Research and Development Expense of Revenue |
8.35% | 6.64% | 6.08% | 5.89% | |
Selling, General and Administrative Expense of Revenue |
48.97% | 48.37% | 40.19% | 43.13% | |
Intangible Assets out of Total Assets |
0.09 | 0.09 | 0.08 | 0.00 | |
Share Based Compensation of Revenue |
1.67% | 1.15% | 1.01% | 1.07% | |
Graham Net Nets |
0.15 | 0.26 | 0.25 | 0.26 | |
Graham Number |
1.51 | 1.22 | 1.97 | 2.14 | |
Earnings Yield |
2.17% | 2.21% | 4.36% | 4.74% | |
Free Cash Flow Yield |
2.94% | (1.49%) | (2.03%) | (2.57%) | |
Revenue per Share |
0.45 | 0.49 | 0.55 | 0.52 | |
Operating CF per Share |
0.02 | (0.16) | 0.06 | (0.01) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.02 | (0.16) | 0.06 | (0.01) | |
Cash per Share |
0.51 | 0.38 | 0.43 | 0.42 | |
Shareholders Equity per Share |
0.96 | 1.00 | 1.10 | 1.16 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.96 | 1.00 | 1.10 | 1.16 | |
Free Cash Flow |
0.23 | (1.67) | 0.68 | (0.15) | |
Working Capital |
8.46 | 8.97 | 10.25 | 10.85 | |
Net Current Asset Value |
7.78 | 8.40 | 9.79 | 10.50 | |
EV/EBIT |
40.48 | 40.96 | 20.75 | 19.55 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
45.19 | 46.88 | 23.61 | 22.04 | |
| Other line items | |||||
Average Receivables |
2.10 | 3.10 | 3.07 | 3.12 | |
Average Payables |
0.78 | 1.01 | 1.30 | 0.89 | |
Average Inventory |
2.92 | 2.79 | 3.39 | 3.85 | |
Average Assets |
12.43 | 12.79 | 14.01 | 14.28 | |
Average Common Equity |
9.39 | 10.00 | 10.78 | 11.28 |
Columns are period end dates · fundamentals updated 5 Nov 2026